Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Free Cash Flow (2016 - 2025)

United Therapeutics' Free Cash Flow history spans 17 years, with the latest figure at $577.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 68.56% year-over-year to $577.5 million; the TTM value through Dec 2025 reached $1.4 billion, up 10.73%, while the annual FY2025 figure was $1.4 billion, 10.73% up from the prior year.
  • Free Cash Flow for Q4 2025 was $577.5 million at United Therapeutics, up from $280.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $577.5 million in Q4 2025 and bottomed at -$44.9 million in Q4 2023.
  • The 5-year median for Free Cash Flow is $228.9 million (2022), against an average of $244.0 million.
  • The largest annual shift saw Free Cash Flow plummeted 135.22% in 2023 before it skyrocketed 863.03% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $174.9 million in 2021, then dropped by 27.1% to $127.5 million in 2022, then tumbled by 135.22% to -$44.9 million in 2023, then surged by 863.03% to $342.6 million in 2024, then skyrocketed by 68.56% to $577.5 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Free Cash Flow are $577.5 million (Q4 2025), $280.7 million (Q3 2025), and $200.4 million (Q2 2025).